MDWD

MediWound Ltd. [MDWD] Stock Forecast

Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000

MDWD Stock Summary

Top 10 Correlated ETFs

MDWD

Top 10 Correlated Stocks

MDWD

In the News

MDWD Financial details

Company Rating
-
Market Cap
151.77M
Income
-6.72M
Revenue
18.69M
Book val./share
-
Cash/share
-
Dividend
-
Dividend %
-
Employees
100
Optionable
No
Shortable
Yes
Earnings
28 May 2024
P/E
-9.26
Forward P/E
-
PEG
1.15
P/S
4.61
P/B
3.48
P/C
-
P/FCF
-11.19
Quick Ratio
5.88
Current Ratio
6.31
Debt / Equity
-
LT Debt / Equity
-
-
-
EPS (TTM)
-0.77
EPS next Y
-
EPS next Q
-
EPS this Y
-80.92%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
NAN%
Revenue last 5Y
-10.08%
Revenue Q/Q
11.77%
EPS Q/Q
-20.83%
-
-
-
-
SMA20
-5.56%
SMA50
-15%
SMA100
-5.56%
Inst Own
-
Inst Trans
-
ROA
-19%
ROE
-44%
ROC
-0.16%
Gross Margin
44%
Oper. Margin
-38%
Profit Margin
-50%
Payout
-
Shs Outstand
-
Shs Float
-
-
-
-
-
Target Price
-
52W Range
7.1-17.25
52W High
+0.53%
52W Low
+144.14%
RSI
45
Rel Volume
0.45
Avg Volume
66.21K
Volume
29.49K
Perf Week
-7.37%
Perf Month
-9%
Perf Quarter
7.15%
Perf Half Y
-10.48%
-
-
-
-
Beta
0.926
-
-
Volatility
0.77%, 0.82%
Prev Close
2.27%
Price
17.09
Change
0.53%

Something similar

Top by Market Cap
AAPL
M&M.NS
3V64.DE
AMZN
LLY.DE
Top Correlated ETFs
091170.KS
091220.KS
UTES
MAXI
CRPT
Top Correlated Stocks
SHG
MAJE.L
001440.KS
055550.KS
035600.KQ
Similar Market Cap
SCCE
1580.HK
BOAC
SKSEX
LKOR.DE

Company Profile

Healthcare Biotechnology
  • Volume Average 66.21K
  • Market Capitalization 151.77M
  • Employee 100
  • CEO Mr. Ofer Gonen B.Sc.
  • Headquarters Yavne,IL
  • IPO Date 2014-03-20
  • Website https://www.mediwound.com

MediWound Ltd., a biopharmaceutical company, develops, manufactures, and commercializes novel and bio-therapeutic solutions for tissue repair and regeneration. It markets NexoBrid, a biopharmaceutical product for the removal of eschar, a dead or damaged tissue in adults with deep partial- and full-thickness thermal burns to burn centers and hospitals burn units. The company also develops EscharEx, which has completed Phase II clinical trials for the debridement of chronic and other hard-to-heal wounds; MW005, which is in phase I/II for the treatment of low-risk basal cell carcinoma. MediWound Ltd. was founded in 2000 and is headquartered in Yavne, Israel.